Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
In acutely ill patients, 10 days of rivaroxaban was noninferior to 10 days of enoxaparin for thromboprophylaxis. Extended-duration rivaroxaban treatment (35 days) reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding. Patients with active cancer, s...
Saved in:
| Published in: | The New England journal of medicine Vol. 368; no. 6; pp. 513 - 523 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Waltham, MA
Massachusetts Medical Society
07.02.2013
|
| Subjects: | |
| ISSN: | 0028-4793, 1533-4406, 1533-4406 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | In acutely ill patients, 10 days of rivaroxaban was noninferior to 10 days of enoxaparin for thromboprophylaxis. Extended-duration rivaroxaban treatment (35 days) reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding.
Patients with active cancer, stroke, myocardial infarction, or acute exacerbations of a variety of medical conditions are at increased risk for venous thromboembolism.
1
Prolonged immobilization and risk factors such as an age older than 75 years, chronic heart failure, a history of venous thromboembolism, and obesity can increase this risk further.
2
,
3
Randomized, controlled trials involving hospitalized patients at increased risk for venous thromboembolism have shown the benefits of administering anticoagulant agents for up to 14 days,
4
–
8
and guidelines recommend the use of unfractionated heparin, low-molecular-weight heparins, or fondaparinux in such patients.
9
There is some evidence that the risk . . . |
|---|---|
| AbstractList | BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg once daily, for 35±4 days. The primary efficacy outcomes were the composite of asymptomatic proximal or symptomatic venous thromboembolism up to day 10 (noninferiority test) and up to day 35 (superiority test). The principal safety outcome was the composite of major or clinically relevant nonmajor bleeding. RESULTS: A total of 8101 patients underwent randomization. A primary efficacy outcome event occurred in 78 of 2938 patients (2.7%) receiving rivaroxaban and 82 of 2993 patients (2.7%) receiving enoxaparin at day 10 (relative risk with rivaroxaban, 0.97; 95% confidence interval [CI], 0.71 to 1.31; P=0.003 for noninferiority) and in 131 of 2967 patients (4.4%) who received rivaroxaban and 175 of 3057 patients (5.7%) who received enoxaparin followed by placebo at day 35 (relative risk, 0.77; 95% CI, 0.62 to 0.96; P=0.02). A principal safety outcome event occurred in 111 of 3997 patients (2.8%) in the rivaroxaban group and 49 of 4001 patients (1.2%) in the enoxaparin group at day 10 (P<0.001) and in 164 patients (4.1%) and 67 patients (1.7%) in the respective groups at day 35 (P<0.001). CONCLUSIONS: In acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-duration thromboprophylaxis. Extended-duration rivaroxaban reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding. (Funded by Bayer HealthCare Pharmaceuticals and Janssen Research and Development; MAGELLAN ClinicalTrials.gov number, NCT00571649.). In acutely ill patients, 10 days of rivaroxaban was noninferior to 10 days of enoxaparin for thromboprophylaxis. Extended-duration rivaroxaban treatment (35 days) reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding. Patients with active cancer, stroke, myocardial infarction, or acute exacerbations of a variety of medical conditions are at increased risk for venous thromboembolism. 1 Prolonged immobilization and risk factors such as an age older than 75 years, chronic heart failure, a history of venous thromboembolism, and obesity can increase this risk further. 2 , 3 Randomized, controlled trials involving hospitalized patients at increased risk for venous thromboembolism have shown the benefits of administering anticoagulant agents for up to 14 days, 4 – 8 and guidelines recommend the use of unfractionated heparin, low-molecular-weight heparins, or fondaparinux in such patients. 9 There is some evidence that the risk . . . The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg once daily, for 35±4 days. The primary efficacy outcomes were the composite of asymptomatic proximal or symptomatic venous thromboembolism up to day 10 (noninferiority test) and up to day 35 (superiority test). The principal safety outcome was the composite of major or clinically relevant nonmajor bleeding. A total of 8101 patients underwent randomization. A primary efficacy outcome event occurred in 78 of 2938 patients (2.7%) receiving rivaroxaban and 82 of 2993 patients (2.7%) receiving enoxaparin at day 10 (relative risk with rivaroxaban, 0.97; 95% confidence interval [CI], 0.71 to 1.31; P=0.003 for noninferiority) and in 131 of 2967 patients (4.4%) who received rivaroxaban and 175 of 3057 patients (5.7%) who received enoxaparin followed by placebo at day 35 (relative risk, 0.77; 95% CI, 0.62 to 0.96; P=0.02). A principal safety outcome event occurred in 111 of 3997 patients (2.8%) in the rivaroxaban group and 49 of 4001 patients (1.2%) in the enoxaparin group at day 10 (P<0.001) and in 164 patients (4.1%) and 67 patients (1.7%) in the respective groups at day 35 (P<0.001). In acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-duration thromboprophylaxis. Extended-duration rivaroxaban reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding. (Funded by Bayer HealthCare Pharmaceuticals and Janssen Research and Development; MAGELLAN ClinicalTrials.gov number, NCT00571649.). The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo.BACKGROUNDThe clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo.We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg once daily, for 35±4 days. The primary efficacy outcomes were the composite of asymptomatic proximal or symptomatic venous thromboembolism up to day 10 (noninferiority test) and up to day 35 (superiority test). The principal safety outcome was the composite of major or clinically relevant nonmajor bleeding.METHODSWe randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg once daily, for 35±4 days. The primary efficacy outcomes were the composite of asymptomatic proximal or symptomatic venous thromboembolism up to day 10 (noninferiority test) and up to day 35 (superiority test). The principal safety outcome was the composite of major or clinically relevant nonmajor bleeding.A total of 8101 patients underwent randomization. A primary efficacy outcome event occurred in 78 of 2938 patients (2.7%) receiving rivaroxaban and 82 of 2993 patients (2.7%) receiving enoxaparin at day 10 (relative risk with rivaroxaban, 0.97; 95% confidence interval [CI], 0.71 to 1.31; P=0.003 for noninferiority) and in 131 of 2967 patients (4.4%) who received rivaroxaban and 175 of 3057 patients (5.7%) who received enoxaparin followed by placebo at day 35 (relative risk, 0.77; 95% CI, 0.62 to 0.96; P=0.02). A principal safety outcome event occurred in 111 of 3997 patients (2.8%) in the rivaroxaban group and 49 of 4001 patients (1.2%) in the enoxaparin group at day 10 (P<0.001) and in 164 patients (4.1%) and 67 patients (1.7%) in the respective groups at day 35 (P<0.001).RESULTSA total of 8101 patients underwent randomization. A primary efficacy outcome event occurred in 78 of 2938 patients (2.7%) receiving rivaroxaban and 82 of 2993 patients (2.7%) receiving enoxaparin at day 10 (relative risk with rivaroxaban, 0.97; 95% confidence interval [CI], 0.71 to 1.31; P=0.003 for noninferiority) and in 131 of 2967 patients (4.4%) who received rivaroxaban and 175 of 3057 patients (5.7%) who received enoxaparin followed by placebo at day 35 (relative risk, 0.77; 95% CI, 0.62 to 0.96; P=0.02). A principal safety outcome event occurred in 111 of 3997 patients (2.8%) in the rivaroxaban group and 49 of 4001 patients (1.2%) in the enoxaparin group at day 10 (P<0.001) and in 164 patients (4.1%) and 67 patients (1.7%) in the respective groups at day 35 (P<0.001).In acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-duration thromboprophylaxis. Extended-duration rivaroxaban reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding. (Funded by Bayer HealthCare Pharmaceuticals and Janssen Research and Development; MAGELLAN ClinicalTrials.gov number, NCT00571649.).CONCLUSIONSIn acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-duration thromboprophylaxis. Extended-duration rivaroxaban reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding. (Funded by Bayer HealthCare Pharmaceuticals and Janssen Research and Development; MAGELLAN ClinicalTrials.gov number, NCT00571649.). |
| Author | Büller, Harry R Haskell, Lloyd Schellong, Sebastian Spiro, Theodore E Hu, Dayi Tapson, Victor Cohen, Alexander T Hull, Russell Spyropoulos, Alex C Mebazaa, Alexandre Merli, Geno |
| Author_xml | – sequence: 1 givenname: Alexander T surname: Cohen fullname: Cohen, Alexander T organization: From King's College Hospital, London (A.T.C.); Bayer HealthCare Pharmaceuticals, Montville (T.E.S.), and Janssen Research and Development, Raritan (L.H.) — both in New Jersey; Academic Medical Center, Amsterdam (H.R.B.); People's Hospital of Peking University, Beijing (D.H.); Foothills Hospital, Calgary, AB, Canada (R.H.); Hôpital Lariboisière, Paris (A.M.); Thomas Jefferson Medical Center, Philadelphia (G.M.); Dresden-Friedrichstadt Hospital, Dresden, Germany (S.S.); Hofstra North Shore–Long Island Jewish School of Medicine, Manhasset, NY (A.C.S.); and Duke University Medical Center, Durham, NC (V.T.) – sequence: 2 givenname: Theodore E surname: Spiro fullname: Spiro, Theodore E organization: From King's College Hospital, London (A.T.C.); Bayer HealthCare Pharmaceuticals, Montville (T.E.S.), and Janssen Research and Development, Raritan (L.H.) — both in New Jersey; Academic Medical Center, Amsterdam (H.R.B.); People's Hospital of Peking University, Beijing (D.H.); Foothills Hospital, Calgary, AB, Canada (R.H.); Hôpital Lariboisière, Paris (A.M.); Thomas Jefferson Medical Center, Philadelphia (G.M.); Dresden-Friedrichstadt Hospital, Dresden, Germany (S.S.); Hofstra North Shore–Long Island Jewish School of Medicine, Manhasset, NY (A.C.S.); and Duke University Medical Center, Durham, NC (V.T.) – sequence: 3 givenname: Harry R surname: Büller fullname: Büller, Harry R organization: From King's College Hospital, London (A.T.C.); Bayer HealthCare Pharmaceuticals, Montville (T.E.S.), and Janssen Research and Development, Raritan (L.H.) — both in New Jersey; Academic Medical Center, Amsterdam (H.R.B.); People's Hospital of Peking University, Beijing (D.H.); Foothills Hospital, Calgary, AB, Canada (R.H.); Hôpital Lariboisière, Paris (A.M.); Thomas Jefferson Medical Center, Philadelphia (G.M.); Dresden-Friedrichstadt Hospital, Dresden, Germany (S.S.); Hofstra North Shore–Long Island Jewish School of Medicine, Manhasset, NY (A.C.S.); and Duke University Medical Center, Durham, NC (V.T.) – sequence: 4 givenname: Lloyd surname: Haskell fullname: Haskell, Lloyd organization: From King's College Hospital, London (A.T.C.); Bayer HealthCare Pharmaceuticals, Montville (T.E.S.), and Janssen Research and Development, Raritan (L.H.) — both in New Jersey; Academic Medical Center, Amsterdam (H.R.B.); People's Hospital of Peking University, Beijing (D.H.); Foothills Hospital, Calgary, AB, Canada (R.H.); Hôpital Lariboisière, Paris (A.M.); Thomas Jefferson Medical Center, Philadelphia (G.M.); Dresden-Friedrichstadt Hospital, Dresden, Germany (S.S.); Hofstra North Shore–Long Island Jewish School of Medicine, Manhasset, NY (A.C.S.); and Duke University Medical Center, Durham, NC (V.T.) – sequence: 5 givenname: Dayi surname: Hu fullname: Hu, Dayi organization: From King's College Hospital, London (A.T.C.); Bayer HealthCare Pharmaceuticals, Montville (T.E.S.), and Janssen Research and Development, Raritan (L.H.) — both in New Jersey; Academic Medical Center, Amsterdam (H.R.B.); People's Hospital of Peking University, Beijing (D.H.); Foothills Hospital, Calgary, AB, Canada (R.H.); Hôpital Lariboisière, Paris (A.M.); Thomas Jefferson Medical Center, Philadelphia (G.M.); Dresden-Friedrichstadt Hospital, Dresden, Germany (S.S.); Hofstra North Shore–Long Island Jewish School of Medicine, Manhasset, NY (A.C.S.); and Duke University Medical Center, Durham, NC (V.T.) – sequence: 6 givenname: Russell surname: Hull fullname: Hull, Russell organization: From King's College Hospital, London (A.T.C.); Bayer HealthCare Pharmaceuticals, Montville (T.E.S.), and Janssen Research and Development, Raritan (L.H.) — both in New Jersey; Academic Medical Center, Amsterdam (H.R.B.); People's Hospital of Peking University, Beijing (D.H.); Foothills Hospital, Calgary, AB, Canada (R.H.); Hôpital Lariboisière, Paris (A.M.); Thomas Jefferson Medical Center, Philadelphia (G.M.); Dresden-Friedrichstadt Hospital, Dresden, Germany (S.S.); Hofstra North Shore–Long Island Jewish School of Medicine, Manhasset, NY (A.C.S.); and Duke University Medical Center, Durham, NC (V.T.) – sequence: 7 givenname: Alexandre surname: Mebazaa fullname: Mebazaa, Alexandre organization: From King's College Hospital, London (A.T.C.); Bayer HealthCare Pharmaceuticals, Montville (T.E.S.), and Janssen Research and Development, Raritan (L.H.) — both in New Jersey; Academic Medical Center, Amsterdam (H.R.B.); People's Hospital of Peking University, Beijing (D.H.); Foothills Hospital, Calgary, AB, Canada (R.H.); Hôpital Lariboisière, Paris (A.M.); Thomas Jefferson Medical Center, Philadelphia (G.M.); Dresden-Friedrichstadt Hospital, Dresden, Germany (S.S.); Hofstra North Shore–Long Island Jewish School of Medicine, Manhasset, NY (A.C.S.); and Duke University Medical Center, Durham, NC (V.T.) – sequence: 8 givenname: Geno surname: Merli fullname: Merli, Geno organization: From King's College Hospital, London (A.T.C.); Bayer HealthCare Pharmaceuticals, Montville (T.E.S.), and Janssen Research and Development, Raritan (L.H.) — both in New Jersey; Academic Medical Center, Amsterdam (H.R.B.); People's Hospital of Peking University, Beijing (D.H.); Foothills Hospital, Calgary, AB, Canada (R.H.); Hôpital Lariboisière, Paris (A.M.); Thomas Jefferson Medical Center, Philadelphia (G.M.); Dresden-Friedrichstadt Hospital, Dresden, Germany (S.S.); Hofstra North Shore–Long Island Jewish School of Medicine, Manhasset, NY (A.C.S.); and Duke University Medical Center, Durham, NC (V.T.) – sequence: 9 givenname: Sebastian surname: Schellong fullname: Schellong, Sebastian organization: From King's College Hospital, London (A.T.C.); Bayer HealthCare Pharmaceuticals, Montville (T.E.S.), and Janssen Research and Development, Raritan (L.H.) — both in New Jersey; Academic Medical Center, Amsterdam (H.R.B.); People's Hospital of Peking University, Beijing (D.H.); Foothills Hospital, Calgary, AB, Canada (R.H.); Hôpital Lariboisière, Paris (A.M.); Thomas Jefferson Medical Center, Philadelphia (G.M.); Dresden-Friedrichstadt Hospital, Dresden, Germany (S.S.); Hofstra North Shore–Long Island Jewish School of Medicine, Manhasset, NY (A.C.S.); and Duke University Medical Center, Durham, NC (V.T.) – sequence: 10 givenname: Alex C surname: Spyropoulos fullname: Spyropoulos, Alex C organization: From King's College Hospital, London (A.T.C.); Bayer HealthCare Pharmaceuticals, Montville (T.E.S.), and Janssen Research and Development, Raritan (L.H.) — both in New Jersey; Academic Medical Center, Amsterdam (H.R.B.); People's Hospital of Peking University, Beijing (D.H.); Foothills Hospital, Calgary, AB, Canada (R.H.); Hôpital Lariboisière, Paris (A.M.); Thomas Jefferson Medical Center, Philadelphia (G.M.); Dresden-Friedrichstadt Hospital, Dresden, Germany (S.S.); Hofstra North Shore–Long Island Jewish School of Medicine, Manhasset, NY (A.C.S.); and Duke University Medical Center, Durham, NC (V.T.) – sequence: 11 givenname: Victor surname: Tapson fullname: Tapson, Victor organization: From King's College Hospital, London (A.T.C.); Bayer HealthCare Pharmaceuticals, Montville (T.E.S.), and Janssen Research and Development, Raritan (L.H.) — both in New Jersey; Academic Medical Center, Amsterdam (H.R.B.); People's Hospital of Peking University, Beijing (D.H.); Foothills Hospital, Calgary, AB, Canada (R.H.); Hôpital Lariboisière, Paris (A.M.); Thomas Jefferson Medical Center, Philadelphia (G.M.); Dresden-Friedrichstadt Hospital, Dresden, Germany (S.S.); Hofstra North Shore–Long Island Jewish School of Medicine, Manhasset, NY (A.C.S.); and Duke University Medical Center, Durham, NC (V.T.) |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27073799$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23388003$$D View this record in MEDLINE/PubMed https://hal.univ-brest.fr/hal-00933269$$DView record in HAL |
| BookMark | eNp10VFrFDEQAOAgFXutPvoqCyLow-pks8kmj2eptnJVkfocstmEy5FNzmS39P69qXdVLDQvgeGbSWbmBB2FGAxCLzG8x0DZh6_nX66iwuWAYE_QAlNC6rYFdoQWAA2v206QY3SS8wbKwa14ho4bQjgHIAv08Ye7USneql6FysZUXa9THPu4TXG73nl163LlQrXU82T8rrr0vroyg9PKV9_V5EyY8nP01CqfzYvDfYp-fjq_PruoV98-X54tV7WmlE_1AKJlHWHUatoKTUxjodcDIwwwqM62WBnc267EsBUDMExszwfOWDfY3jJyit7t666Vl9vkRpV2MionL5YreRcDEIQ0TNzgYt_ubenj12zyJEeXtfFeBRPnLHHDacsKpoW-fkA3cU6hdPJHYQ6cQlGvDmruRzP8ff9-kgW8OQCVy3RsUkG7_M910JFOiOLI3ukUc07GSu2mMskYpqSclxjk3V7lf3stWfWDrPvCj_nDb8Yxy2A24yPuN_ckrFo |
| CODEN | NEJMAG |
| CitedBy_id | crossref_primary_10_1007_s11739_017_1714_9 crossref_primary_10_2217_cpr_14_2 crossref_primary_10_3390_jcm9082467 crossref_primary_10_1073_pnas_1504229112 crossref_primary_10_1055_s_0040_1715798 crossref_primary_10_4103_0972_5229_133902 crossref_primary_10_1002_rth2_12343 crossref_primary_10_1016_j_mayocp_2018_07_020 crossref_primary_10_1016_j_mcna_2025_02_003 crossref_primary_10_1056_NEJMc1303641 crossref_primary_10_4137_CMT_S18890 crossref_primary_10_1016_j_ahj_2021_02_001 crossref_primary_10_1177_1076029619853629 crossref_primary_10_1177_1358863X14534309 crossref_primary_10_1016_j_medcle_2018_07_005 crossref_primary_10_1016_S1470_2045_16_30369_2 crossref_primary_10_1177_2047487319836572 crossref_primary_10_1515_acm_2017_0008 crossref_primary_10_1007_s00277_024_05767_z crossref_primary_10_1160_TH14_03_0239 crossref_primary_10_1007_s00415_014_7462_0 crossref_primary_10_1186_s12959_021_00326_2 crossref_primary_10_1097_JS9_0000000000000778 crossref_primary_10_1097_MOH_0000000000000369 crossref_primary_10_1007_s11239_015_1297_0 crossref_primary_10_1111_jth_13140 crossref_primary_10_1007_s40265_019_01084_2 crossref_primary_10_1161_JAHA_117_006015 crossref_primary_10_1080_21548331_2020_1772639 crossref_primary_10_1161_JAHA_122_025342 crossref_primary_10_1161_CIR_0000000000000769 crossref_primary_10_1080_17474086_2022_2098104 crossref_primary_10_1016_j_jss_2020_10_009 crossref_primary_10_1007_s11739_016_1427_5 crossref_primary_10_1160_TH15_02_0131 crossref_primary_10_1007_s11936_023_00998_1 crossref_primary_10_1160_TH16_08_0595 crossref_primary_10_1016_j_ijcard_2014_11_101 crossref_primary_10_1056_NEJMoa1805090 crossref_primary_10_7759_cureus_15497 crossref_primary_10_1007_s13670_016_0163_z crossref_primary_10_1161_JAHA_117_007338 crossref_primary_10_1160_TH16_04_0302 crossref_primary_10_1097_SPC_0000000000000309 crossref_primary_10_1186_s12959_015_0040_6 crossref_primary_10_1097_CCM_0000000000004306 crossref_primary_10_1016_j_beha_2013_07_011 crossref_primary_10_1177_1358863X231159945 crossref_primary_10_2217_fca_15_31 crossref_primary_10_1111_jgs_12799 crossref_primary_10_1007_s40256_015_0122_7 crossref_primary_10_2217_fca_13_98 crossref_primary_10_1016_j_jacc_2021_12_012 crossref_primary_10_5937_sjait2502005B crossref_primary_10_5315_wjh_v9_i2_13 crossref_primary_10_1016_j_beha_2013_07_002 crossref_primary_10_2217_fca_15_87 crossref_primary_10_1182_blood_2016_10_747931 crossref_primary_10_1053_j_seminoncol_2016_11_009 crossref_primary_10_2217_fca_2018_0076 crossref_primary_10_1097_MBC_0000000000001132 crossref_primary_10_3390_tropicalmed6010026 crossref_primary_10_1007_s11739_017_1723_8 crossref_primary_10_1016_j_thromres_2016_06_008 crossref_primary_10_1016_j_lpm_2013_06_002 crossref_primary_10_1056_NEJMoa1814630 crossref_primary_10_1055_s_0043_1769013 crossref_primary_10_1016_j_blre_2020_100743 crossref_primary_10_1007_s11239_021_02456_w crossref_primary_10_1080_14779072_2018_1484281 crossref_primary_10_1002_ajh_26945 crossref_primary_10_1016_j_amjcard_2021_03_017 crossref_primary_10_3109_21678421_2014_984724 crossref_primary_10_1097_MBC_0000000000000291 crossref_primary_10_1161_ATVBAHA_114_304488 crossref_primary_10_3390_cancers16020450 crossref_primary_10_1002_rth2_12292 crossref_primary_10_1016_S0049_3848_14_50022_9 crossref_primary_10_1002_pdi_2014 crossref_primary_10_1002_jhm_2282 crossref_primary_10_1016_j_thromres_2017_10_012 crossref_primary_10_1016_j_cgh_2024_10_031 crossref_primary_10_1016_j_revmed_2020_12_014 crossref_primary_10_1016_j_thromres_2023_05_011 crossref_primary_10_15446_rsap_v22n3_87321 crossref_primary_10_2217_fca_2018_0052 crossref_primary_10_1182_bloodadvances_2020004118 crossref_primary_10_1097_SLA_0000000000000904 crossref_primary_10_1111_joim_13735 crossref_primary_10_1007_s00134_019_05605_1 crossref_primary_10_1007_s11739_018_1956_1 crossref_primary_10_1160_th14_08_0671 crossref_primary_10_1161_CIRCULATIONAHA_116_026170 crossref_primary_10_1136_bcr_2013_009973 crossref_primary_10_1161_JAHA_120_019459 crossref_primary_10_1016_j_amjmed_2018_08_024 crossref_primary_10_1186_s42358_020_00125_9 crossref_primary_10_1161_JAHA_122_026229 crossref_primary_10_1016_j_ejim_2014_07_005 crossref_primary_10_1097_FJC_0000000000001485 crossref_primary_10_1002_ejhf_1153 crossref_primary_10_1016_j_jacc_2016_11_024 crossref_primary_10_1007_s11239_020_02138_z crossref_primary_10_1007_s11739_020_02536_4 crossref_primary_10_1055_s_0040_1714738 crossref_primary_10_1160_TH17_03_0168 crossref_primary_10_1007_s00520_022_07137_9 crossref_primary_10_1177_10760296241256368 crossref_primary_10_1016_j_arcmed_2020_11_002 crossref_primary_10_1055_a_2537_6037 crossref_primary_10_1016_j_ejvs_2021_10_054 crossref_primary_10_1007_s11864_020_00744_w crossref_primary_10_1177_10760296251319961 crossref_primary_10_1160_TH17_03_0171 crossref_primary_10_1016_S0049_3848_16_30108_6 crossref_primary_10_1186_s13018_025_06092_5 crossref_primary_10_1016_j_thromres_2020_11_013 crossref_primary_10_1007_s12325_018_0846_2 crossref_primary_10_1177_1076029618823287 crossref_primary_10_1007_s40265_015_0526_3 crossref_primary_10_1160_TH13_02_0170 crossref_primary_10_1160_TH14_06_0484 crossref_primary_10_1007_s11739_013_0979_x crossref_primary_10_1016_j_mcna_2015_02_006 crossref_primary_10_1007_s11239_019_01943_5 crossref_primary_10_1016_j_avsg_2013_07_013 crossref_primary_10_1185_03007995_2015_1098599 crossref_primary_10_1016_j_amjms_2017_03_011 crossref_primary_10_1177_1076029619850897 crossref_primary_10_1097_PRS_0000000000006407 crossref_primary_10_1016_j_sapharm_2022_07_004 crossref_primary_10_1016_j_thromres_2020_11_001 crossref_primary_10_1177_1358863X18821159 crossref_primary_10_1177_1358863X221115213 crossref_primary_10_1182_bloodadvances_2019000840 crossref_primary_10_7861_clinmedicine_14_2_165 crossref_primary_10_1016_j_carbpol_2022_120072 crossref_primary_10_1016_j_jacc_2017_09_024 crossref_primary_10_1016_j_thromres_2019_06_002 crossref_primary_10_1177_1076029612474840i crossref_primary_10_1016_j_hlc_2021_04_018 crossref_primary_10_1016_j_ccm_2018_04_002 crossref_primary_10_1016_j_jacc_2020_09_543 crossref_primary_10_1097_MEG_0000000000002035 crossref_primary_10_1016_j_rvm_2013_10_005 crossref_primary_10_1016_j_jemermed_2019_10_011 crossref_primary_10_1177_15910199211035894 crossref_primary_10_1016_j_amjmed_2018_02_029 crossref_primary_10_1097_TA_0000000000003853 crossref_primary_10_1186_s12959_023_00469_4 crossref_primary_10_1007_s11239_019_01878_x crossref_primary_10_1016_j_thromres_2014_06_013 crossref_primary_10_1177_1074248413501392 crossref_primary_10_1097_HPC_0000000000000232 crossref_primary_10_1016_j_jvsv_2013_04_006 crossref_primary_10_1183_13993003_01887_2016 crossref_primary_10_1111_jth_14146 crossref_primary_10_3389_fphar_2018_00575 crossref_primary_10_1186_s12959_019_0196_6 crossref_primary_10_1182_bloodadvances_2018022954 crossref_primary_10_1007_s15027_013_0178_8 crossref_primary_10_1007_s11239_021_02376_9 crossref_primary_10_1093_bja_aet401 crossref_primary_10_2217_fca_13_76 crossref_primary_10_1016_j_disamonth_2018_03_003 crossref_primary_10_3892_etm_2019_8019 crossref_primary_10_1007_s11239_016_1422_8 crossref_primary_10_1016_j_jacc_2020_04_031 crossref_primary_10_1097_PHM_0000000000002570 crossref_primary_10_1016_j_beha_2022_101347 crossref_primary_10_1177_1076029616677802 crossref_primary_10_1055_s_0041_1723018 crossref_primary_10_1200_JCO_2014_55_4980 crossref_primary_10_1016_j_hrthm_2016_12_038 crossref_primary_10_1080_14779072_2018_1534068 crossref_primary_10_1097_MJT_0000000000000055 crossref_primary_10_1161_CIRCHEARTFAILURE_112_000381 crossref_primary_10_1371_journal_pone_0086094 crossref_primary_10_1016_j_jstrokecerebrovasdis_2022_106700 crossref_primary_10_1016_j_clinthera_2018_10_009 crossref_primary_10_1016_j_ejim_2017_05_029 crossref_primary_10_1016_j_mayocp_2013_11_015 crossref_primary_10_1016_j_thromres_2020_06_005 crossref_primary_10_1056_NEJMoa1601747 crossref_primary_10_2146_ajhp170785 crossref_primary_10_1182_bloodadvances_2020001804 crossref_primary_10_1016_S0049_3848_14_50027_8 crossref_primary_10_1097_PCC_0000000000003648 crossref_primary_10_1016_j_microc_2024_111744 crossref_primary_10_1080_14779072_2017_1305889 crossref_primary_10_1056_NEJMoa1716771 crossref_primary_10_1111_jth_14131 crossref_primary_10_1080_00325481_2015_1022494 crossref_primary_10_1016_j_cgh_2017_04_031 crossref_primary_10_15446_revfacmed_v64n2_49963 crossref_primary_10_1007_s40265_014_0261_1 crossref_primary_10_1016_j_mcna_2016_03_007 crossref_primary_10_36290_vnl_2019_010 crossref_primary_10_1007_s11239_019_01900_2 crossref_primary_10_1159_000540107 crossref_primary_10_1016_j_ijcard_2016_12_168 crossref_primary_10_1016_j_amjmed_2020_01_037 crossref_primary_10_1002_14651858_CD014541_pub2 crossref_primary_10_1093_ndt_gfaa337 crossref_primary_10_3389_fcvm_2016_00024 crossref_primary_10_7326_ACPJC_2018_169_12_064 crossref_primary_10_1161_CIRCULATIONAHA_123_063901 crossref_primary_10_1177_1076029620936350 crossref_primary_10_3390_jcm9041002 crossref_primary_10_1007_s40138_019_00191_4 crossref_primary_10_1016_j_jacc_2019_11_028 crossref_primary_10_1136_bmj_2022_070022 crossref_primary_10_1007_s00717_023_00537_0 crossref_primary_10_1053_j_seminhematol_2014_03_006 crossref_primary_10_1080_14656566_2016_1241233 crossref_primary_10_1053_j_seminhematol_2014_03_002 crossref_primary_10_1016_j_thromres_2019_10_027 crossref_primary_10_1016_j_jtha_2025_04_005 crossref_primary_10_1161_JAHA_122_025914 crossref_primary_10_1016_j_ahj_2017_12_015 crossref_primary_10_1007_s00277_025_06380_4 crossref_primary_10_1016_j_jaccao_2021_03_001 crossref_primary_10_1007_s11886_020_01327_9 crossref_primary_10_1182_bloodadvances_2023010067 crossref_primary_10_1080_14656566_2018_1558209 crossref_primary_10_1016_S2352_3026_15_00228_8 crossref_primary_10_1515_med_2018_0085 crossref_primary_10_1080_21548331_2021_2007648 crossref_primary_10_1161_CIR_0000000000001063 crossref_primary_10_1155_2021_8886210 crossref_primary_10_1016_j_thromres_2015_02_024 crossref_primary_10_1136_bmjebm_2018_111057 crossref_primary_10_1136_postgradmedj_2014_132605 crossref_primary_10_1177_2042098613507945 crossref_primary_10_15829_1560_4071_2020_1_3678 crossref_primary_10_3310_hta21090 crossref_primary_10_1007_s00104_021_01568_6 crossref_primary_10_1161_CIRCULATIONAHA_120_046702 crossref_primary_10_1164_rccm_201302_0230ED crossref_primary_10_1016_j_thromres_2018_07_010 crossref_primary_10_1016_j_ccl_2013_07_001 crossref_primary_10_1182_bloodadvances_2022007017 crossref_primary_10_1007_s11239_017_1481_5 crossref_primary_10_1177_10760296211069082 crossref_primary_10_1016_j_amjmed_2019_05_050 crossref_primary_10_1038_nrcardio_2013_73 crossref_primary_10_1097_CRD_0000000000000227 crossref_primary_10_1080_14737140_2021_1941889 crossref_primary_10_1016_j_amjmed_2019_12_001 crossref_primary_10_1161_JAHA_113_000136 crossref_primary_10_1378_chest_13_2993 crossref_primary_10_1007_s12325_013_0041_4 crossref_primary_10_1155_2015_920361 crossref_primary_10_1111_bjh_19424 crossref_primary_10_1016_j_chest_2019_05_025 crossref_primary_10_1016_S0140_6736_21_02392_8 crossref_primary_10_1177_1060028015578451 crossref_primary_10_1016_j_thromres_2017_04_011 crossref_primary_10_1177_1076029620948137 crossref_primary_10_1001_jama_2021_17272 crossref_primary_10_1007_s00108_014_3476_z crossref_primary_10_1002_rth2_12827 crossref_primary_10_1160_TH14_07_0604 crossref_primary_10_1038_s41575_021_00492_8 crossref_primary_10_3390_jcm7020029 crossref_primary_10_1177_00185787221122656 crossref_primary_10_1160_TH16_10_0823 crossref_primary_10_1007_s00347_021_01438_w crossref_primary_10_1016_j_thromres_2018_01_028 crossref_primary_10_1007_s00415_021_10448_2 crossref_primary_10_1111_imj_14417 crossref_primary_10_1016_S0049_3848_14_50009_6 crossref_primary_10_1097_EJA_0000000000000630 crossref_primary_10_1016_j_jvsv_2017_08_019 crossref_primary_10_18087_cardio_2020_6_n1180 crossref_primary_10_1016_j_amjmed_2013_09_015 crossref_primary_10_1016_j_disamonth_2016_03_003 crossref_primary_10_1016_j_jacc_2020_05_023 crossref_primary_10_1038_s41598_021_94160_1 crossref_primary_10_3390_life11101032 crossref_primary_10_1111_scd_12485 crossref_primary_10_1097_MOH_0b013e328363c170 crossref_primary_10_1177_1076029619856433 crossref_primary_10_1111_crj_13438 crossref_primary_10_1007_s40265_019_1059_y crossref_primary_10_1007_s10741_024_10422_w crossref_primary_10_1016_j_jvsvi_2025_100201 crossref_primary_10_1080_14737175_2016_1181542 crossref_primary_10_1182_blood_2016_12_758995 crossref_primary_10_1177_10760296211053316 crossref_primary_10_1007_s40256_023_00579_4 crossref_primary_10_1016_S0049_3848_14_50008_4 crossref_primary_10_1016_j_thromres_2014_08_014 crossref_primary_10_1177_10600280231178335 crossref_primary_10_1016_j_jaad_2014_11_013 crossref_primary_10_1177_1358863X20932640 crossref_primary_10_1016_j_ejim_2021_09_016 crossref_primary_10_1016_j_tmaid_2013_11_005 crossref_primary_10_1007_s40262_013_0100_7 crossref_primary_10_1016_j_amjcard_2018_06_035 crossref_primary_10_1111_eci_13433 crossref_primary_10_1007_s11239_022_02689_3 crossref_primary_10_1007_s11940_023_00747_6 crossref_primary_10_1007_s40278_013_1601_8 crossref_primary_10_1177_1076029619886022 crossref_primary_10_1007_s40261_021_01061_2 crossref_primary_10_1093_eurheartj_suy018 crossref_primary_10_1177_1076029614561321 crossref_primary_10_1093_eurheartj_suy015 crossref_primary_10_1093_eurheartj_suy016 crossref_primary_10_2147_TCRM_S271439 crossref_primary_10_1093_eurheartj_suy017 crossref_primary_10_1182_bloodadvances_2020003442 crossref_primary_10_1111_jth_12683 crossref_primary_10_1111_nyas_12136 crossref_primary_10_3390_clinpract12050080 crossref_primary_10_1016_j_ijcard_2015_10_204 crossref_primary_10_1016_j_rce_2014_12_009 crossref_primary_10_1016_j_avsg_2020_11_007 crossref_primary_10_1016_j_cgh_2019_05_056 crossref_primary_10_1136_bmj_2022_072715 crossref_primary_10_1111_jth_12698 crossref_primary_10_1177_1358863X18818319 crossref_primary_10_1007_s13546_015_1022_1 crossref_primary_10_1007_s11239_014_1082_5 crossref_primary_10_1111_jth_12338 crossref_primary_10_1161_JAHA_121_021579 crossref_primary_10_1161_CIRCRESAHA_116_306925 crossref_primary_10_1007_s11739_013_0970_6 crossref_primary_10_1111_jth_13783 crossref_primary_10_5858_arpa_2013_0750_OA crossref_primary_10_1016_j_ygyno_2015_07_017 crossref_primary_10_1186_1477_9560_11_18 crossref_primary_10_14694_EdBook_AM_2013_33_e337 crossref_primary_10_1016_j_nurpra_2020_04_002 crossref_primary_10_1016_j_cjca_2013_04_013 crossref_primary_10_1080_17474086_2023_2162499 crossref_primary_10_1111_jth_14600 crossref_primary_10_1164_rccm_201301_0141PP crossref_primary_10_7326_M20_0347 crossref_primary_10_1177_10760296211008999 crossref_primary_10_5005_jp_journals_10071_24195 crossref_primary_10_1016_j_rpth_2024_102549 crossref_primary_10_1016_j_ahj_2013_11_006 crossref_primary_10_1080_00325481_2021_1876387 crossref_primary_10_1016_j_ejim_2023_03_032 crossref_primary_10_1007_s11239_017_1583_0 crossref_primary_10_1160_TH15_09_0756 crossref_primary_10_1016_j_bja_2021_05_035 crossref_primary_10_1055_a_2374_3425 crossref_primary_10_1186_s12890_024_02915_z crossref_primary_10_1055_s_0040_1714273 crossref_primary_10_1161_CIRCULATIONAHA_121_057847 crossref_primary_10_1016_S0049_3848_16_30113_X crossref_primary_10_1080_14737167_2019_1629905 crossref_primary_10_1056_NEJMc1613217 crossref_primary_10_1177_0885066618796486 crossref_primary_10_1016_j_jaad_2020_10_008 crossref_primary_10_1016_j_jdmv_2020_04_008 crossref_primary_10_1111_ejh_12610 crossref_primary_10_1007_s11239_013_0955_3 crossref_primary_10_1002_phar_2102 crossref_primary_10_1002_phar_2465 crossref_primary_10_1055_s_0041_1722992 crossref_primary_10_1182_blood_2020007938 crossref_primary_10_5937_arhfarm2005284T crossref_primary_10_1136_heartjnl_2013_305288 crossref_primary_10_1007_s40273_018_0757_8 crossref_primary_10_1016_j_tacc_2021_05_004 crossref_primary_10_1080_17474086_2017_1343662 crossref_primary_10_1007_s11739_018_1953_4 crossref_primary_10_1093_ajhp_zxab039 crossref_primary_10_1016_j_thromres_2013_08_013 crossref_primary_10_1016_j_jmv_2014_02_001 crossref_primary_10_1016_j_lpm_2013_10_001 crossref_primary_10_1016_j_urology_2024_03_042 crossref_primary_10_3389_fmed_2020_00280 crossref_primary_10_1055_s_0042_1744302 crossref_primary_10_1111_jth_13626 crossref_primary_10_7861_clinmedicine_13_6_s53 crossref_primary_10_1080_21548331_2018_1410053 crossref_primary_10_1136_postgradmedj_2013_132474 crossref_primary_10_1159_000365967 crossref_primary_10_1016_j_revmed_2021_03_323 crossref_primary_10_1016_j_jtha_2025_02_044 crossref_primary_10_1007_s11739_018_1843_9 crossref_primary_10_1002_rth2_12560 crossref_primary_10_1017_dmp_2020_195 crossref_primary_10_1007_s40256_019_00329_5 crossref_primary_10_1111_jth_14929 crossref_primary_10_1111_apt_15286 crossref_primary_10_1586_14779072_2013_811979 crossref_primary_10_1124_jpet_124_002203 crossref_primary_10_1177_8755122518759765 crossref_primary_10_1177_00368504211012160 crossref_primary_10_1093_ajhp_zxaa286 crossref_primary_10_1161_CIRCULATIONAHA_113_003126 crossref_primary_10_1007_s11239_017_1562_5 crossref_primary_10_1111_jth_13606 crossref_primary_10_1016_j_hlc_2024_04_167 crossref_primary_10_1177_1060028018754383 crossref_primary_10_1007_s11239_016_1461_1 crossref_primary_10_1111_jth_12515 crossref_primary_10_1016_j_cll_2014_06_009 crossref_primary_10_1146_annurev_med_051113_024633 |
| Cites_doi | 10.1001/archinte.160.22.3415 10.1001/archinte.167.14.1471 10.1001/archinte.164.9.963 10.7326/0003-4819-153-1-201007060-00004 10.1161/01.CIR.0000138928.83266.24 10.1007/s11239-011-0549-x 10.1160/TH05-06-0385 10.1164/ajrccm.161.4.9807025 10.1378/chest.08-0656 10.1136/bmj.38733.466748.7C 10.1378/chest.09-3081 10.7326/0003-4819-146-4-200702200-00007 10.1056/NEJMoa1110899 10.1056/NEJM199909093411103 |
| ContentType | Journal Article |
| Contributor | Francis, C van Zandweghe, L Bergeron, C Merli, G Peters, R G J Carroll, P Voorend, M Hall, S Leizorovicz, A Bizzacchi, J M A Prins, M Bauer, N C Weidinger, F Nessel, C Hu, D Dimov, D Otten, H M Schönherr, H-R Cohen, A T Jackson, D Colquhoun, D Lyubenov, L Kirchmair, P Schellong, S Fiss, E Hemmrich, M Beckmann, H Mac Gillavry, M R Leyden, M Fortunat, W Caberlotto, O Siostrzonek, P Hull, R Mühlhofer, E Grand, B van Roey, G Hojman, M Haskell, L Robben, S Balcke, P Lowe, G Baker, R Garicochea, B Mykietiuk, A Weltermann, A Spyropoulos, A C Hendler, H Fielding, L Meng, I Mebazaa, A Spiro, T Grafl, E Mincheva, V Desanctis, Y Wenisch, C Salerno, R Gan, E Twomey, T Milanov, S Büller, H Chong, B Müller, K Ivanov, Y Vanden Abeele, A Taseva, M Duszczyszyn, A Striekwold, H Limburg, M L Soupart, A Li, L Erlacher, L Delobbe, A Blockmans, D Brandges, D Keil, F van Bellen, B Pilger, E Jacquy, C Popov, D Chamone, D Tapson, V Kobayashi, S Salem, H Cavalheiro, C Boulanger, J-M Nenkova, S Hendrickx, K Atkinson, Sarah van Hoof, M-E Byra, W Serisier, D Buck, B Bottaro, F J Roberts, R Rocha Moreira, R |
| Contributor_xml | – sequence: 1 givenname: H surname: Büller fullname: Büller, H – sequence: 2 givenname: A T surname: Cohen fullname: Cohen, A T – sequence: 3 givenname: L surname: Haskell fullname: Haskell, L – sequence: 4 givenname: D surname: Hu fullname: Hu, D – sequence: 5 givenname: R surname: Hull fullname: Hull, R – sequence: 6 givenname: A surname: Mebazaa fullname: Mebazaa, A – sequence: 7 givenname: G surname: Merli fullname: Merli, G – sequence: 8 givenname: S surname: Schellong fullname: Schellong, S – sequence: 9 givenname: T surname: Spiro fullname: Spiro, T – sequence: 10 givenname: A C surname: Spyropoulos fullname: Spyropoulos, A C – sequence: 11 givenname: V surname: Tapson fullname: Tapson, V – sequence: 12 givenname: C surname: Francis fullname: Francis, C – sequence: 13 givenname: S surname: Kobayashi fullname: Kobayashi, S – sequence: 14 givenname: A surname: Leizorovicz fullname: Leizorovicz, A – sequence: 15 givenname: G surname: Lowe fullname: Lowe, G – sequence: 16 givenname: R surname: Roberts fullname: Roberts, R – sequence: 17 givenname: D surname: Brandges fullname: Brandges, D – sequence: 18 givenname: D surname: Kolbach fullname: Kolbach, D – sequence: 19 givenname: M L surname: Limburg fullname: Limburg, M L – sequence: 20 givenname: M R surname: Mac Gillavry fullname: Mac Gillavry, M R – sequence: 21 givenname: H M surname: Otten fullname: Otten, H M – sequence: 22 givenname: R G J surname: Peters fullname: Peters, R G J – sequence: 23 givenname: M surname: Prins fullname: Prins, M – sequence: 24 givenname: S surname: Robben fullname: Robben, S – sequence: 25 givenname: M surname: Voorend fullname: Voorend, M – sequence: 26 givenname: M surname: Hemmrich fullname: Hemmrich, M – sequence: 27 givenname: L surname: Li fullname: Li, L – sequence: 28 givenname: I surname: Meng fullname: Meng, I – sequence: 29 givenname: E surname: Mühlhofer fullname: Mühlhofer, E – sequence: 30 givenname: H surname: Beckmann fullname: Beckmann, H – sequence: 31 givenname: Y surname: Desanctis fullname: Desanctis, Y – sequence: 32 givenname: A surname: Duszczyszyn fullname: Duszczyszyn, A – sequence: 33 givenname: L surname: Fielding fullname: Fielding, L – sequence: 34 givenname: T surname: Twomey fullname: Twomey, T – sequence: 35 givenname: K surname: Müller fullname: Müller, K – sequence: 36 givenname: W surname: Byra fullname: Byra, W – sequence: 37 givenname: C surname: Nessel fullname: Nessel, C – sequence: 38 givenname: Sarah surname: Atkinson fullname: Atkinson, Sarah – sequence: 39 givenname: F J surname: Bottaro fullname: Bottaro, F J – sequence: 40 givenname: O surname: Caberlotto fullname: Caberlotto, O – sequence: 41 givenname: B surname: Grand fullname: Grand, B – sequence: 42 givenname: H surname: Hendler fullname: Hendler, H – sequence: 43 givenname: M surname: Hojman fullname: Hojman, M – sequence: 44 givenname: A surname: Mykietiuk fullname: Mykietiuk, A – sequence: 45 givenname: R surname: Salerno fullname: Salerno, R – sequence: 46 givenname: R surname: Baker fullname: Baker, R – sequence: 47 givenname: P surname: Carroll fullname: Carroll, P – sequence: 48 givenname: B surname: Chong fullname: Chong, B – sequence: 49 givenname: D surname: Colquhoun fullname: Colquhoun, D – sequence: 50 givenname: E surname: Gan fullname: Gan, E – sequence: 51 givenname: S surname: Hall fullname: Hall, S – sequence: 52 givenname: D surname: Jackson fullname: Jackson, D – sequence: 53 givenname: M surname: Leyden fullname: Leyden, M – sequence: 54 givenname: H surname: Salem fullname: Salem, H – sequence: 55 givenname: D surname: Serisier fullname: Serisier, D – sequence: 56 givenname: P surname: Balcke fullname: Balcke, P – sequence: 57 givenname: B surname: Bauer fullname: Bauer, B – sequence: 58 givenname: N C surname: Bauer fullname: Bauer, N C – sequence: 59 givenname: L surname: Erlacher fullname: Erlacher, L – sequence: 60 givenname: W surname: Fortunat fullname: Fortunat, W – sequence: 61 givenname: E surname: Grafl fullname: Grafl, E – sequence: 62 givenname: F surname: Keil fullname: Keil, F – sequence: 63 givenname: P surname: Kirchmair fullname: Kirchmair, P – sequence: 64 givenname: E surname: Pilger fullname: Pilger, E – sequence: 65 givenname: H-R surname: Schönherr fullname: Schönherr, H-R – sequence: 66 givenname: P surname: Siostrzonek fullname: Siostrzonek, P – sequence: 67 givenname: F surname: Weidinger fullname: Weidinger, F – sequence: 68 givenname: A surname: Weltermann fullname: Weltermann, A – sequence: 69 givenname: C surname: Wenisch fullname: Wenisch, C – sequence: 70 givenname: D surname: Blockmans fullname: Blockmans, D – sequence: 71 givenname: A surname: Delobbe fullname: Delobbe, A – sequence: 72 givenname: K surname: Hendrickx fullname: Hendrickx, K – sequence: 73 givenname: C surname: Jacquy fullname: Jacquy, C – sequence: 74 givenname: A surname: Soupart fullname: Soupart, A – sequence: 75 givenname: H surname: Striekwold fullname: Striekwold, H – sequence: 76 givenname: M-E surname: van Hoof fullname: van Hoof, M-E – sequence: 77 givenname: A surname: Vanden Abeele fullname: Vanden Abeele, A – sequence: 78 givenname: G surname: van Roey fullname: van Roey, G – sequence: 79 givenname: L surname: van Zandweghe fullname: van Zandweghe, L – sequence: 80 givenname: J M A surname: Bizzacchi fullname: Bizzacchi, J M A – sequence: 81 givenname: C surname: Cavalheiro fullname: Cavalheiro, C – sequence: 82 givenname: D surname: Chamone fullname: Chamone, D – sequence: 83 givenname: E surname: Fiss fullname: Fiss, E – sequence: 84 givenname: B surname: Garicochea fullname: Garicochea, B – sequence: 85 givenname: A C surname: Lopes fullname: Lopes, A C – sequence: 86 givenname: R C surname: Rocha Moreira fullname: Rocha Moreira, R C – sequence: 87 givenname: B surname: van Bellen fullname: van Bellen, B – sequence: 88 givenname: D surname: Dimov fullname: Dimov, D – sequence: 89 givenname: Y surname: Ivanov fullname: Ivanov, Y – sequence: 90 givenname: L surname: Lyubenov fullname: Lyubenov, L – sequence: 91 givenname: S surname: Milanov fullname: Milanov, S – sequence: 92 givenname: V surname: Mincheva fullname: Mincheva, V – sequence: 93 givenname: S surname: Nenkova fullname: Nenkova, S – sequence: 94 givenname: D surname: Popov fullname: Popov, D – sequence: 95 givenname: M surname: Taseva fullname: Taseva, M – sequence: 96 givenname: C surname: Bergeron fullname: Bergeron, C – sequence: 97 givenname: J-M surname: Boulanger fullname: Boulanger, J-M – sequence: 98 givenname: B surname: Buck fullname: Buck, B |
| Copyright | Copyright © 2013 Massachusetts Medical Society. All rights reserved. 2014 INIST-CNRS Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: Copyright © 2013 Massachusetts Medical Society. All rights reserved. – notice: 2014 INIST-CNRS – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| CorporateAuthor | MAGELLAN Investigators |
| CorporateAuthor_xml | – name: MAGELLAN Investigators |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 1XC |
| DOI | 10.1056/NEJMoa1111096 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library SciTech Premium Collection New England Journal of Medicine Biological Sciences Consumer Health Database Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic Hyper Article en Ligne (HAL) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: ProQuest Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-4406 |
| EndPage | 523 |
| ExternalDocumentID | oai:HAL:hal-00933269v1 2886696111 23388003 27073799 10_1056_NEJMoa1111096 NJ201302073680606 |
| Genre | Original Article Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | - 0R 0WA 123 186 1KJ 1VV 29N 2KS 2WC 34G 39C 3V. 4 4.4 53G 55 5D0 5RE 68V 7FN 7RV 7X7 85S 8AO 8C1 8FE 8FH 8FI AACLI AAEJM AAIKC AAJWC AALRV AAPBV AAQQT AARDX AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQIJ ABUWG ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACRZS ADBBV ADBIT ADCBC ADRHT AENEX AETEA AFFNX AFHKK AFKRA AGFXO AGNAY AHMBA AJJEV AJVPN ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI AZQEC BBAFP BBNVY BCR BCU BENPR BES BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C45 CJ0 CO CS3 DCD DU5 DWQXO DZ EBS EJD ET EX3 F20 F5P FD8 FM. FYUFA GJ GNUQQ GUQSH H13 HCIFZ HZ IH2 K-O KM KOO L7B LK8 M0R M0T M1P M2M M2O M2P M7P MVM N9A NAPCQ NEJ O9- OK1 OMK OVD P-O P-S P2P PADUT PCD PEA PQEST PQQKQ PQUKI PRINS PROAC PSQYO QJJ RHI RWL RXW S10 S6N SJFOW SJN TAE TAF TEORI TN5 TUQ TWZ UCV UKR UMD UQL VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZHY ZKB --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 1CY 36B 6TJ AAMNW AAYXX ABBLC ABCQX ABDQB ABJNI ABUFD ACKOT ACPFK ADUKH ADXHL AERZD AFFHD AGHSJ BYPQX CCPQU CITATION HF~ HMCUK HZ~ N4W PHGZM PHGZT PJZUB PPXIY PQGLB PSYQQ UKHRP YFH YR2 YR5 YYP ZCA ZR0 ZVN ~KM 3O- 41~ 8WZ 9M8 A6W AAQOH AAUTI ABDPE ABEFU ACPVT ACTDY AFFDN AFOSN AJUXI ALIPV D0S FA8 IQODW J5H LPU MQT NHB OHT QZG SKT UBX WHG XOL YHZ YQI YQJ YYQ ZGI ZXP CGR CUY CVF ECM EIF NPM UIG 7XB BEC K0Y MBDVC PKEHL Q9U 7X8 PUEGO 1XC |
| ID | FETCH-LOGICAL-c558t-d09467365fc549c3e2f0bcd636010a7f41ae1bf7bcd1f9d0613fb8d8667dfbf63 |
| IEDL.DBID | DCD |
| ISICitedReferencesCount | 469 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000314494100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Sat Nov 29 15:04:58 EST 2025 Thu Oct 02 03:52:38 EDT 2025 Tue Oct 07 05:32:46 EDT 2025 Thu Apr 03 07:00:33 EDT 2025 Mon Jul 21 09:13:56 EDT 2025 Sat Nov 29 03:54:34 EST 2025 Tue Nov 18 22:22:13 EST 2025 Tue Dec 21 14:38:50 EST 2021 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Vascular disease Human Medicine Prevention Rivaroxaban Antithrombotic agent Cardiovascular disease Patient Thrombosis |
| Language | English |
| License | CC BY 4.0 Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c558t-d09467365fc549c3e2f0bcd636010a7f41ae1bf7bcd1f9d0613fb8d8667dfbf63 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-General Information-1 content type line 14 ObjectType-Feature-3 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0001-8715-7753 |
| OpenAccessLink | https://www.nejm.org/doi/pdf/10.1056/NEJMoa1111096?articleTools=true |
| PMID | 23388003 |
| PQID | 1285180850 |
| PQPubID | 40644 |
| PageCount | 11 |
| ParticipantIDs | hal_primary_oai_HAL_hal_00933269v1 proquest_miscellaneous_1285463265 proquest_journals_1285180850 pubmed_primary_23388003 pascalfrancis_primary_27073799 crossref_citationtrail_10_1056_NEJMoa1111096 crossref_primary_10_1056_NEJMoa1111096 mms_nejm_10_1056_NEJMoa1111096 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-02-07 |
| PublicationDateYYYYMMDD | 2013-02-07 |
| PublicationDate_xml | – month: 02 year: 2013 text: 2013-02-07 day: 07 |
| PublicationDecade | 2010 |
| PublicationPlace | Waltham, MA |
| PublicationPlace_xml | – name: Waltham, MA – name: United States – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationTitleAlternate | N Engl J Med |
| PublicationYear | 2013 |
| Publisher | Massachusetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society |
| References | Hull, RD, Schellong, SM, Tapson, VF (r011) 2010; 153 Dentali, F, Douketis, JD, Gianni, M, Lim, W, Crowther, MA (r004) 2007; 146 Cohen, AT, Alikhan, R, Arcelus, JI (r001) 2005; 94 Geerts, WH, Bergqvist, D, Pineo, GF (r009) 2008; 133 Leizorovicz, A, Cohen, AT, Turpie, AGG, Olsson, CG, Vaitkus, PT, Goldhaber, SZ (r007) 2004; 110 Cohen, AT, Spiro, TE, Buller, HR (r013) 2011; 31 Samama, MM (r002) 2000; 160 Alikhan, R, Cohen, AT, Combe, S (r003) 2004; 164 Spencer, FA, Lessard, D, Emery, C, Reed, G, Goldberg, RJ (r010) 2007; 167 Decousus, H, Tapson, VF, Bergmann, JF (r015) 2011; 139 Cohen, AT, Davidson, BL, Gallus, AS (r008) 2006; 332 r014 Fraisse, F, Holzapfel, L, Couland, JM (r006) 2000; 161 Goldhaber, SZ, Leizorovicz, A, Kakkar, AK (r012) 2011; 365 Samama, MM, Cohen, AT, Darmon, JY (r005) 1999; 341 Cohen AT (r001) 2005; 94 r010 r011 r012 r006 r007 r008 r009 r002 r013 r003 r004 r015 r005 23675668 - N Engl J Med. 2013 May 16;368(20):1945 23940851 - Rev Clin Esp (Barc). 2013 Jun-Jul;213(5):257 23675666 - N Engl J Med. 2013 May 16;368(20):1944-5 23675667 - N Engl J Med. 2013 May 16;368(20):1945 23675665 - N Engl J Med. 2013 May 16;368(20):1945-6 |
| References_xml | – volume: 153 start-page: 8 year: 2010 end-page: 18 ident: r011 article-title: Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. publication-title: Ann Intern Med – volume: 94 start-page: 750 year: 2005 end-page: 759 ident: r001 article-title: Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. publication-title: Thromb Haemost – volume: 133 start-page: 381S year: 2008 end-page: 453S ident: r009 article-title: Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). ;:Suppl publication-title: Chest – volume: 341 start-page: 793 year: 1999 end-page: 800 ident: r005 article-title: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. publication-title: N Engl J Med – volume: 160 start-page: 3415 year: 2000 end-page: 3420 ident: r002 article-title: An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. publication-title: Arch Intern Med – volume: 167 start-page: 1471 year: 2007 end-page: 1475 ident: r010 article-title: Venous thromboembolism in the outpatient setting. publication-title: Arch Intern Med – volume: 164 start-page: 963 year: 2004 end-page: 968 ident: r003 article-title: Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. publication-title: Arch Intern Med – volume: 332 start-page: 325 year: 2006 end-page: 329 ident: r008 article-title: Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. publication-title: BMJ – volume: 365 start-page: 2167 year: 2011 end-page: 2177 ident: r012 article-title: Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. publication-title: N Engl J Med – volume: 139 start-page: 69 year: 2011 end-page: 79 ident: r015 article-title: Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. publication-title: Chest – volume: 31 start-page: 407 year: 2011 end-page: 416 ident: r013 article-title: Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. publication-title: J Thromb Thrombolysis – volume: 161 start-page: 1109 year: 2000 end-page: 1114 ident: r006 article-title: Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. publication-title: Am J Respir Crit Care Med – ident: r014 – volume: 146 start-page: 278 year: 2007 end-page: 288 ident: r004 article-title: Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. publication-title: Ann Intern Med – volume: 110 start-page: 874 year: 2004 end-page: 879 ident: r007 article-title: Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. publication-title: Circulation – ident: r002 doi: 10.1001/archinte.160.22.3415 – ident: r010 doi: 10.1001/archinte.167.14.1471 – ident: r003 doi: 10.1001/archinte.164.9.963 – ident: r011 doi: 10.7326/0003-4819-153-1-201007060-00004 – ident: r007 doi: 10.1161/01.CIR.0000138928.83266.24 – ident: r013 doi: 10.1007/s11239-011-0549-x – volume: 94 start-page: 750 year: 2005 ident: r001 publication-title: Thromb Haemost doi: 10.1160/TH05-06-0385 – ident: r006 doi: 10.1164/ajrccm.161.4.9807025 – ident: r009 doi: 10.1378/chest.08-0656 – ident: r008 doi: 10.1136/bmj.38733.466748.7C – ident: r015 doi: 10.1378/chest.09-3081 – ident: r004 doi: 10.7326/0003-4819-146-4-200702200-00007 – ident: r012 doi: 10.1056/NEJMoa1110899 – ident: r005 doi: 10.1056/NEJM199909093411103 – reference: 23940851 - Rev Clin Esp (Barc). 2013 Jun-Jul;213(5):257 – reference: 23675666 - N Engl J Med. 2013 May 16;368(20):1944-5 – reference: 23675665 - N Engl J Med. 2013 May 16;368(20):1945-6 – reference: 23675667 - N Engl J Med. 2013 May 16;368(20):1945 – reference: 23675668 - N Engl J Med. 2013 May 16;368(20):1945 |
| SSID | ssj0000149 |
| Score | 2.592458 |
| Snippet | In acutely ill patients, 10 days of rivaroxaban was noninferior to 10 days of enoxaparin for thromboprophylaxis. Extended-duration rivaroxaban treatment (35... The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized,... Background The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter,... BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter,... |
| SourceID | hal proquest pubmed pascalfrancis crossref mms |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 513 |
| SubjectTerms | Acute Disease Administration, Oral Adult Aged Anticoagulants Anticoagulants - adverse effects Anticoagulants - therapeutic use Asymptomatic Biological and medical sciences Double-Blind Method Drug Administration Schedule Enoxaparin Enoxaparin - adverse effects Enoxaparin - therapeutic use Factor Xa Factor Xa Inhibitors Female General aspects Heart attacks Hemorrhage Hemorrhage - chemically induced Hospitalization Humans Injections, Subcutaneous Life Sciences Male Medical sciences Middle Aged Morpholines Morpholines - adverse effects Morpholines - therapeutic use Prevention and actions Public health. Hygiene Public health. Hygiene-occupational medicine Pulmonary embolisms Rivaroxaban Thiophenes Thiophenes - adverse effects Thiophenes - therapeutic use Thromboembolism Thrombosis Ultrasonic imaging Veins & arteries Venous Thromboembolism Venous Thromboembolism - epidemiology Venous Thromboembolism - prevention & control |
| SummonAdditionalLinks | – databaseName: Science Database dbid: M2P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb9MwED7RgRAvjN-EjcogxBPRaidO4qepQ0xD2qYKDWlvkePYWlGajKatxn_PXeJ220N54dWxLok_--58d_oO4BNqPKdtXIZCWhnGSuuwUAiIM2RNnZBlT5J0mp6fZ5eXauIDbq0vq1zrxE5Rl42hGPkB6lHJMyJYO7z-HVLXKMqu-hYaA3iIng2nkq4zMblDH-XdXx9B8hybaPMPqNN8o0lfjIiv_45NGlxRReRgNmupTlK3uFSu73Gx3QntjNHx7v_-xjN46t1QNu73zXN4YOsX8PjMJ9pfwtGP6UrPmxtd6JqhX8surubNrGjwbYhLpW-mLZvWbGyWC1v9Yd-rivmUD5v0TK3tK_h5_O3i60no2y2ERspsEZZ406MqL-kMXhpNZIUbFaYkQjE-0qmLuba8cCmOcadKcgRckSGWSVq6wiXRa9ipm9q-BZaZVMvMSJ1xF4s4KQQee8EjYxKrCmUC-LJe8Nx4LnJqiVHlXU5cJvk9fAL4vJl-3ZNwbJv4EdHbzCHq7JPxaU5jXehGJGrFAxgiuHltf822SRnew30jT6SoEFOlAthfg5v7I9_mt8gG8GHzGA8rZWB0bZtlPydO8DNkAG_6DXQrPCJenlH07t_C9-CJ6DpyUNHwPuws5kv7Hh6Z1WLazofd_v8L1OEJCA priority: 102 providerName: ProQuest |
| Title | Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients |
| URI | https://nejm.org/doi/full/10.1056/NEJMoa1111096 https://www.ncbi.nlm.nih.gov/pubmed/23388003 https://www.proquest.com/docview/1285180850 https://www.proquest.com/docview/1285463265 https://hal.univ-brest.fr/hal-00933269 |
| Volume | 368 |
| WOSCitedRecordID | wos000314494100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBGY databaseName: New England Journal of Medicine Current customDbUrl: eissn: 1533-4406 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: DCD dateStart: 19900101 isFulltext: true titleUrlDefault: https://www.nejm.org/medical-index providerName: Massachusetts Medical Society – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M7P dateStart: 19800103 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0R dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7X7 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0T dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: BENPR dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Nursing & Allied Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7RV dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2M dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 8C1 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2O dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2P dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db5swED817TTtZd8fbB1i07SnoQaDMTymaatOajIUZVPekDG2monAFJKo--93ByRbNEXTXn4PxljWnc93-MzvAD7gjmekDnKXcc3dIJbSzWJUiFHkTQ3jeUuSdCPG42g2i5MjONv-C1Pq74smgU8WTSfQ2-rwZ1QbvpJk4Rh19-CE1hot44vhxR98UV282x0ZdaSaf72-54R6t3QFsrdY1HQxUtYoG9MWtTgcdTbe5-rRf8_7MTzsAk1n0K6MJ3Cky6dwf9Sl0p_B-WS-kcvqTmaydDBydaa3y2qRVTgVlHwh7-a1My-dgVqvdPHT-VwUTpfUcZKWi7V-Dl-vLqfDa7crqOAqzqOVm-O3HN3j4kbhZ6HyNTP9TOVEGeb1pTCBJ7WXGYFtnolzcvUmi1BbochNZkL_BRyXValfgRMpIXmkuIw8E7AgzBgaNvN8pUIdZ7Gy4NNWwqnq2Map6EWRNllvHqZ7crHg4677j5Zm41DH96iuXR8ix74e3KTU1hzOsDDeeBbYqM2UdHJoFHtP0bvxmMAtT8SxBadbzaedUdcpunLuRcTxZ8G73WM0R8qxyFJX67ZPEOI0uAUv2xXze3CfmHf6_ut_Te8NPGBN1Q26GHwKx6vlWr-Fe2qzmtdLG3pi8o1wJhqMEKOhZ8PJ-eU4mdiNSSCO-pMGp4Rs1OCXBhNCkfwCADcDTA |
| linkProvider | Massachusetts Medical Society |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtNAFL1qCqJseD8MJRgEXWHVHnv8WCAUHlWiplGEgtSdGY9n1FSOXeIktD_FN3KvH2m7CLsu2Nqjq7HnzJnrmetzAN4h42mhvNRiXHHLi4SwkggHREtaTTXjaS2SNAxGo_D4OBpvwZ_2Xxgqq2w5sSLqtJC0R76PPMqdkATWPp39ssg1ik5XWwuNGhaH6uI3frKVHwdfcXzfM3bwbfKlbzWuApbkPFxYqU2u8q7PtcRvI-kqpu1EpqSb5dgi0J4jlJPoAK85OkppvdNJiF32g1Qn2ncxbgdueaQsRqWCbHxFrqpJt5sdq0bTE3OMfXK2LwTxk03-AFfWwM4JVWB2ZrOS6jJFiUOja0-NzUlvtfgd3P_fXtsDuNek2WavnhcPYUvlj-DOUVNI8Bg-f5-uxLw4F4nITczbzcnJvJglBT4d4i4T59PSnOZmTy4XKrswB1lmNkda5rhWoi2fwI8beYKnsJ0XuXoOZigDwUPJRehoj3l-wpDWmONK6asoiaQBH9oBjmWjtU6WH1lcnflzP76GBwP21s3PapGRTQ3fIlrWbUgavN8bxnSt2ppifrRyDOgimOJcnc42Relew9k6HguQ8IMoMmC3BVPcUFoZXyLJgDfr20hGdMIkclUs6zaej93gBjyrAXsZ3CXdIdt98e_gr2GnPzkaxsPB6PAl3GWV-wgVSO_C9mK-VK_gtlwtpuW8W809E37eNGr_Ata0Z3M |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB41BVVceD8MJRgEnLBir71-HBAKlKhR0yiqitSbu17vqkGOXeIktH-NX8eMH2l7CLceuNqr0a7325nZ3fH3AbxHj6eF8lKLccUtLxLCSiKcEC0pmmrG05okaRSMx-HJSTTZgj_tvzBUVtn6xMpRp4WkM_Ie-lHuhESw1tNNWcRkb_Dl_JdFClJ009rKadQQOVCXv3H7Vn4e7uFcf2Bs8P34277VKAxYkvNwYaU2Kcy7PtcS90nSVUzbiUyJQ8uxRaA9Rygn0QE-c3SUUuzTSYjd94NUJ9p30W4H7gQeZ8Tbf2gfXaOualLv5vSq4ffEfKNHKveFIF9lk1bAtXjYOaNqzM5sVlKNpihxmnStr7E5Aa4C4eDB__wJH8L9Jv02-_V6eQRbKn8MO4dNgcET-Ho0XYl5cSESkZuYz5vHZ_NilhQ4UsRjJi6mpTnNzb5cLlR2aQ6zzGyuusxJzVBbPoUftzKCZ7CdF7l6AWYoA8FDyUXoaI95fsLQ3THHldJXURJJAz61kx3LhoOdpECyuKoF4H58AxsGfFw3P6_JRzY1fIfIWbchyvD9_iimZ9WRFfOjlWNAF4EV5-rnbJOV7g3Mre2xAANBEEUG7LbAihtXV8ZXqDLg7fo1Oim6eRK5KpZ1G8_HbnADntfgvTLuEh-R7b78t_E3sINgjUfD8cEruMcqURKqm96F7cV8qV7DXblaTMt5t1qGJpzeNmj_AlvYcDY |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rivaroxaban+for+thromboprophylaxis+in+acutely+ill+medical+patients&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Cohen%2C+Alexander+T&rft.au=Spiro%2C+Theodore+E&rft.au=B%C3%BCller%2C+Harry+R&rft.au=Haskell%2C+Lloyd&rft.date=2013-02-07&rft.issn=1533-4406&rft.eissn=1533-4406&rft.volume=368&rft.issue=6&rft.spage=513&rft_id=info:doi/10.1056%2FNEJMoa1111096&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |